JFJohn Mark Flack

John Mark Flack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Mark Flack has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Gregory Buhnerkempe

    Department of Internal Medicine, Southern Illinois University School of Medicine , Springfield, IL

    6 shared publications
  • Albert Botchway

    Department of Internal Medicine, Southern Illinois University School of Medicine , Springfield, IL

    3 shared publications
  • Ji-Guang Wang

    Centre for Epidemiological Studies and Clinical Trials, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

    3 shared publications
  • Michael Buhnerkempe

    Department of Medicine, Center for Clinical Research, Southern Illinois University School of Medicine , Springfield, IL , USA

    3 shared publications
  • Stephanie Bitner

    Department of Internal Medicine, Southern Illinois University School of Medicine , Springfield, IL

    3 shared publications
  • Vivek Prakash

    Department of Internal Medicine, Southern Illinois University School of Medicine , Springfield, IL

    3 shared publications

Latest Publications

  • Link of Obesity With Primary Aldosteronism: Causal or Not?

    by John M. Flack, Michael G. Buhnerkempe, Angel Lopez, James Brian Byrd

    Obesity has been shown to correlate directly with circulating aldosterone levels and urinary aldosterone excretion in normotensive and hypertensive individuals without primary aldosteronism (PA). This relationship may be bi-directional, though it is probably not symmetrical. Activation of the mineralocorticoid receptor in adipocytes may cause expansion of visceral fat mass. Conversely, adipocytes have been shown to augment the adrenal production of aldosterone by their release of aldosterone secretagogues—leptin, C1q/TNF-related proteins 1, and resistin—into the circulation. Patients with PA are more obese (idiopathic hyperaldosteronism>aldosterone-producing adenoma) than those with essential or no hypertension (women>men). The stronger association of obesity with idiopathic hyperaldosteronism than with the more metabolically severe unilateral PA, and the reductions in aldosterone levels after weight loss, suggest a substantive role for adipocytes in circulating aldosterone levels. A 2-sample Mendelian randomization analysis suggested that peri-renal adipose tissue, a form of visceral adipose tissue encompassing the adrenal glands, was causally linked to idiopathic hyperaldosteronism but not to other forms of hypertension. These observations support the speculation that at least a portion of idiopathic hyperaldosteronism cases represent adipocyte-driven hyperaldosteronism that might be effectively treated by weight loss. This review will provide the trans-disciplinary rationale for the hypothesis supporting a causal relationship between obesity and idiopathic hyperaldosteronism. This unproven hypothesis is eminently testable given the powerful pharmacological and surgical weight loss strategies currently available.


  • Controversies, Challenges, and Dilemmas in Primary Aldosteronism

    by John M. Flack, Adina F. Turcu, Jordana B. Cohen

  • Open Access

    Sodium, potassium, and calories: implications for implementing a recommended diet in adults with hypertension

    by Michael G Buhnerkempe, Avani Yaganti, Stephanie Bitner, Zachary Settelmyer, Ananya Yaganti, Annah Carney, Vivek Prakash, Albert Botchway, Asad Cheema, John M Flack

    Background: Achieving evidence-based dietary recommendations for sodium and potassium are key lifestyle modifications for adults with hypertension. This study aimed to investigate how dietary recommendations have been followed in US adults with hypertension over time. Methods: Cross-sectional data on adults with hypertension was pooled from 12 National Health and Nutrition Examination Surveys (1999-2023). Dietary electrolyte intake was stratified as: (1) sodium ≤2300 mg/day (recommended) or ≤1500 mg/day (ideal), and (2) potassium ≥3500 mg/day (recommended) or ≥4700 mg/day (ideal). Results: From 1999 to 2023, 29.4% (95% confidence interval: 28.6-30.1) and 20.3% (19.6-21.0) of adults with hypertension met recommended sodium and potassium intakes, respectively, with 1.3% (1.1-1.5) meeting both levels. Adults with hypertension meeting ideal intakes for sodium, potassium, and both represented 9.5% (9.1-10.0), 6.1% (5.7-6.6), and 0.03% (0.01-0.06), respectively. The proportion meeting recommended thresholds for sodium has followed a U-shape over time reaching a minimum [24.3% (21.6-26.9)] in 2011-12 before increasing to 34.5% (31.3-37.7) in 2021-23 (P < .001). The proportion meeting the recommended potassium intake, however, has declined over time [yearly prevalence ratio = 0.99 (0.98-0.99), P < .001] reaching the lowest point [15.3% (13.5-17.0)] in 2021-23. The correlations between intakes of sodium and potassium, calories and sodium, and calories and potassium were 0.62, 0.77, and 0.71, respectively. Conclusions: A low percentage of adults with hypertension met both recommended sodium and potassium intakes with higher intakes of potassium associated with high sodium and calories.

  • Top Cited Papers
    Open Access

    Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension

    by Patrick Rossignol, Martine Clozel, Roland F. Dreier, John M. Flack, Bruno Flamion, Johannes Mann, Krzysztof Narkiewicz, Mouna Sassi-Sayadi, Ji-Guang Wang, Michael A. Weber, et al.

    BACKGROUND: Hypertension is a cause and consequence of chronic kidney disease (CKD). Resistant hypertension is common and often difficult to control in patients with CKD. This post hoc analysis evaluated the efficacy and safety of aprocitentan (with standardized background antihypertensive therapy) in patients with CKD and resistant hypertension, a group with high morbidity and mortality risk and limited treatment options. METHODS: The PRECISION study (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) consisted of part 1: 4-week, double-blind (aprocitentan 12.5 and 25 mg versus placebo); part 2: 32-week, single-blind (aprocitentan 25 mg); and part 3: 12-week, double-blind withdrawal (aprocitentan 25 mg versus placebo). In participants with CKD, aprocitentan’s effect on blood pressure (BP), urine albumin-to-creatinine ratio, and safety was evaluated. RESULTS: Of 730 participants in PRECISION, 147 had CKD categorized as KDIGO high risk or very high risk. At week 4, aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo reduced office systolic BP by −13.5, −16.6, and −4.4 mm Hg, respectively; this was maintained with aprocitentan 25 mg to week 36 (−16.4 mm Hg). At week 4, reductions in nighttime ambulatory systolic BP were −9.6, −13.8, and −2.5 mm Hg, respectively. Changes in urine albumin-to-creatinine ratio were −47.1%, −59.6%, and −2.4%, respectively, maintained with aprocitentan 25 mg to week 36 (−61.6%). Aprocitentan was generally well tolerated (no change in potassium or estimated glomerular filtration rate); early peripheral edema was the most common adverse event. CONCLUSIONS: Aprocitentan was well tolerated; efficiently lowered BP, particularly nighttime ambulatory BP; and markedly reduced urine albumin-to-creatinine ratio in participants with CKD and resistant hypertension. Aprocitentan may confer considerable cardiovascular and kidney-protective benefits in these difficult-to-treat patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03541174.


  • Expanding the Search for Primary Aldosteronism in Clinical Settings

    by John M. Flack, Michael G. Buhnerkempe, Garry L.R. Jennings


  • Open Access

    Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24

    by John M. Flack, Michel Azizi, Jenifer M. Brown, Jamie P. Dwyer, Erika S. W. Jones, Aina S. Lihn, Lylian Liu, Daniel S. Olsson, Shira Perl, Hirotaka Shibata, et al.

    Inappropriately elevated aldosterone is a common feature of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), and is a major pathophysiological driver of adverse cardiorenal outcomes beyond elevated blood pressure (BP). Baxdrostat is a selective aldosterone synthase inhibitor that has demonstrated dose-dependent seated office systolic BP (SBP) lowering in a Phase 2 trial of patients with rHTN. Here, we report the design of the baxdrostat hypertension Phase 3 program. BaxHTN (NCT06034743), BaxAsia (NCT06344104), and Bax24 (NCT06168409) are randomized, multi-national, double-blind, placebo-controlled Phase 3 trials evaluating the efficacy and safety of baxdrostat 1 and/or 2 mg versus placebo. BaxHTN includes patients with uHTN or rHTN, BaxAsia includes patients with uHTN or rHTN primarily from Asia, and Bax24 includes patients with rHTN. Eligibility criteria include age ≥18 years, mean seated office SBP of ≥140 mmHg to <170 mmHg at screening, and ≥2 antihypertensive treatments of different classes for ≥4 weeks before screening. BaxHTN and BaxAsia have four sequential periods following placebo run-in: 12-week double-blind; 12-week open-label; 8-week randomized withdrawal; 20-week open-label. Bax24 has a placebo run-in and 12-week double-blind period. Primary endpoints are changes from baseline to Week 12 in mean seated office SBP (BaxHTN and BaxAsia) and ambulatory 24-h average SBP (Bax24). Safety and tolerability are also assessed. The Baxdrostat hypertension Phase 3 program will assess efficacy, long-term sustained effect, and safety profile in patients with hypertension across multiple geographies. The trials will evaluate the BP lowering efficacy of aldosterone synthase inhibition as a novel treatment for uHTN and rHTN.


  • Open Access

    Blood Pressure–Elevating and Antihypertensive Medication Prescription Trends

    by Ashutosh Kumar, Nicole L. Therrien, John I. Ogwuegbu, Jun Soo Lee, Hilary K. Wall, John M. Flack, Sandra L. Jackson

    BACKGROUND: Many medications can have blood pressure (BP)–elevating effects, which might negatively impact BP control among people with hypertension. This study examines trends in prescription fills for BP-elevating and antihypertensive medications, individually and concurrently, among US individuals. METHODS: Quarterly trends of individual and concurrent fills for BP-elevating and antihypertensive medications were reported using the nationwide sample from IQVIA’s Total Patient Tracker database, covering 94% of all retail prescription fills in the United States. We identified 1387 products containing BP-elevating medications and 240 products containing antihypertensive medications. Percentage change from Q1/2017 and average quarterly percent change from the joinpoint regression were used to present trends overall and by sex and age group (0–17, 18–44, 45–64, 65–74, and ≥75 years). RESULTS: From 2017 to 2023, fills remained stable for BP-elevating medications alone and increased for antihypertensive medications alone (9.5% increase; from 10.1% to 11.0%; P P <0.001). Fills for BP-elevating medications were higher among adult women compared with men; among women aged 18 to 44 years, this was primarily due to the use of combined oral contraceptives. In Q4/2023, fills for BP-elevating medications were most common among those aged 65 to 74 years (women=30.7%; men=20.4%). CONCLUSIONS: These results provide the first nationwide trends in concurrent prescription fills for BP-elevating and antihypertensive medications, indicating an increasing trend. Our findings might inform clinician decision-making regarding medication selection for patients with hypertension.


  • Open Access

    Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

    by John M. Flack

    Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?


  • Open Access

    Aprocitentan for Blood Pressure Reduction in Black Patients

    by John M. Flack, Markus P. Schlaich, Michael A. Weber, Mouna Sassi-Sayadi, Krzysztof Narkiewicz, Martine Clozel, Roland F. Dreier, Nabil S. Andrawis, Parisa Danaietash, Nashwa Gabra, et al.

    BACKGROUND: Black individuals frequently present with resistant hypertension and disproportionately increased cardiovascular risk. We investigated the blood pressure (BP)-lowering effect of the dual endothelin receptor antagonist aprocitentan in Black individuals enrolled in the PRECISION study (Parallel-Group, Phase 3 Study with Aprocitentan in Subjects with Resistant Hypertension). METHODS: Patients with confirmed resistant hypertension were randomized to aprocitentan 12.5 mg, 25 mg, or placebo for 4 weeks (part 1). They subsequently received aprocitentan 25 mg for 32 weeks (part 2) before re-randomization to aprocitentan 25 mg or placebo (part 3). RESULTS: Eighty-two patients randomized in the PRECISION study were Black individuals. At week 4, aprocitentan 12.5 and 25 mg reduced office trough systolic BP (−11.3 and −11.9 mm Hg) to a similar degree as placebo (−12.0 mm Hg). Using 24-hour ambulatory BP monitoring, the placebo effect was minimal (−0.7 mm Hg), and aprocitentan reduced systolic BP by 4.0 and 8.6 mm Hg. During part 2, office BP continued to decrease (−16.4 mm Hg at week 36). In part 3, office and ambulatory systolic BP increased on placebo (+9.9 and +8.1 mm Hg, respectively), whereas the BP-lowering effect was maintained with aprocitentan. Aprocitentan markedly reduced albuminuria during the study. The most frequent adverse event was peripheral edema, occurring in 3 patients (10%) receiving aprocitentan 25 mg versus none receiving aprocitentan 12.5 mg or placebo. CONCLUSIONS: Aprocitentan reduced BP and albuminuria in Black individuals with resistant hypertension. The BP-lowering efficacy was similar to that of the overall PRECISION population. Aprocitentan may represent an important addition to the often difficult-to-control hypertension in Black individuals. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03541174.